0000000000132679

AUTHOR

Maria Rosa Barcellona

showing 6 related works from this author

Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease

2011

Aliment Pharmacol Ther 2012; 35: 238–247 Summary Background  Metabolic factors have been associated with liver damage in patients with non-alcoholic fatty liver disease (NAFLD). Aims  To test a new marker of adipose dysfunction, the visceral adiposity index (VAI), in NAFLD patients to assess whether or not it is associated with host factors, and to investigate a potential correlation with histological findings. Methods  One hundred and forty-two consecutive NAFLD patients were evaluated by liver biopsy, and clinical and metabolic measurements, including insulin resistance with the homeostasis model assessment (HOMA), and VAI by using waist circumference, body mass index, triglycerides and H…

medicine.medical_specialtyHepatologyAdiponectinmedicine.diagnostic_testbusiness.industryLeptinFatty liverGastroenterologynutritional and metabolic diseasesAdipose tissuemedicine.diseaseEndocrinologyInsulin resistanceFibrosisInternal medicineLiver biopsymedicinePharmacology (medical)businessBody mass indexAlimentary Pharmacology & Therapeutics
researchProduct

PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

2013

Background and Aim To evaluate if the presence of carotid atherosclerosis in patients with NAFLD, could be related to gene variants influencing hepatic fat accumulation and the severity of liver damage. Methods We recorded anthropometric, metabolic and histological data(Kleiner score) of 162 consecutive, biopsy-proven Sicilian NAFLD patients. Intima-media thickness(IMT), IMT thickening(IMT≥1 mm) and carotid plaques(focal thickening of >1.3 mm at the level of common carotid artery) were evaluated using ultrasonography. IL28B rs12979860 C>T, PNPLA3 rs738409 C>G, GCKR rs780094 C>T, LYPLAL1 rs12137855 C>T, and NCAN rs2228603 C>T single nucleotide polymorphisms were also assessed. The results we…

Carotid Artery DiseasesMalePathologylcsh:MedicineGastroenterology0302 clinical medicinePolymorphism (computer science)Non-alcoholic Fatty Liver DiseaseRisk FactorsGenotypeCommon carotid arterylcsh:ScienceATEROSCLEROSI0303 health sciencesMultidisciplinaryNONALCOHOLIC STEATOHEPATITISFatty liverMiddle Aged3. Good healthCarotid ArteriesCohortcardiovascular system030211 gastroenterology & hepatologyFemaleResearch ArticleAdultmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesmedicine.arteryDiabetes mellitusInternal medicinemedicineHumansClinical significancecardiovascular diseasesAllelesGenetic Association StudiesPNPLA3030304 developmental biologyAgedNAFLD PNPLA3 ATHEROSCLEROSISbusiness.industrylcsh:RMembrane ProteinsLipasemedicine.diseaseFatty Liverlcsh:Qbusiness
researchProduct

Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.

2012

Background and Aims: Serum levels of γ-glutamyl-transpeptidase(γ-GT) were associated with liver disease severity and metabolic alterations, which in turn are able to affect hepatic damage. In patients with nonalcoholic fatty liver disease (NAFLD), genotype 1 chronic hepatitis C (G1CHC) and chronic hepatitis B (CHB), we assessed the link between liver fibrosis and γ-GT serum levels, and we evaluated if normal or high γ-GT serum levels affect the association between insulin resistance (IR) and severity of liver fibrosis. Methods: 843 consecutive patients with chronic liver disease (CLD)(193 NAFLD, 481 G1CHC, 169 CHB) were evaluated by liver biopsy (Kleiner and Scheuer scores) and clinical and…

Liver CirrhosisMalePathologylcsh:MedicineNonalcoholic SteatohepatitisChronic liver diseaseBiochemistryGastroenterologyCohort StudiesLiver diseaseEndocrinologyRisk FactorsFibrosisNonalcoholic fatty liver diseaseInsulinGamma-glutamyltransferaselcsh:ScienceSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testbiologyEnzyme ClassesLiver DiseasesFatty livergamma glutamyl transferase liver fibrosis insulin resistancegamma-GlutamyltransferaseMiddle AgedEnzymesLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignGastroenterology and HepatologySettore MED/08 - Anatomia PatologicaTransferasesInternal medicinemedicineHumansStatistical MethodsBiologyDemographyEndocrine PhysiologyInfectious Hepatitisbusiness.industrylcsh:Rmedicine.diseaseChronic DiseaseMultivariate Analysisbiology.proteinlcsh:QInsulin ResistanceLiver function testsbusinessPLoS ONE
researchProduct

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease

2020

Background & Aims Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk for liver-related complications, such as decompensation, hepatocellular carcinoma (HCC), and death; the severity of liver fibrosis and metabolic comorbidities are the main risk factors. A single nucleotide polymorphism in patatin-like phospholipase domain-containing-3 (PNPLA3) gene is associated with higher prevalence of liver damage and HCC, but there are no data from prospective studies of outcomes of patients with this polymorphism. We investigated whether the common rs738409 variant in PNPLA3 gene associates with the occurrence of liver-related events and death in a large cohort of patients w…

Liver Cancermedicine.medical_specialtyCirrhosisCarcinoma HepatocellularGenotypeGastroenterologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansDecompensationGenetic Predisposition to DiseaseProspective StudiesProspective cohort studyHepatologyProportional hazards modelbusiness.industryPrognostic FactorRisk FactorHazard ratioLiver NeoplasmsGastroenterologyMembrane ProteinsLong-Term OutcomeLipasemedicine.disease030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologybusinessLiver cancer
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct